Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia

In contrast with the classic form, variant hairy cell leukemia (HCLv) responds poorly to single-agent purine analogs, expresses unmutated BRAF, has shorter overall survival, and lacks effective standard therapy. No treatment has achieved a high complete remission (CR) rate even in small series, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2013-12, Vol.19 (24), p.6873-6881
Hauptverfasser:	KREITMAN, Robert J, WILSON, Wyndham, CALVO, Katherine R, ARONS, Evgeny, ROTH, Laura, SAPOLSKY, Jeffrey, HONG ZHOU, RAFFELD, Mark, STETLER-STEVENSON, Maryalice
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Murine-Derived - administration & dosage Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Biological and medical sciences Cladribine - administration & dosage Female Hematologic and hematopoietic diseases Humans Immunoglobulin Heavy Chains - genetics Leukemia, Hairy Cell - drug therapy Leukemia, Hairy Cell - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Pharmacology. Drug treatments Remission Induction Rituximab Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!